In its November meeting, the AIFA Board of Directors approved the admission for reimbursement by the National Health Service of 16 medicines (14 active ingredients), including orphan medicines for rare diseases (3), new molecules (7) and extensions of therapeutic indications (6). 

The authorised orphan drugs are two medicines for the treatment of rare cancers and one enzyme therapy. Among the new molecules, AIFA authorised medicinal products for multiple sclerosis, atopic dermatitis, multiple myeloma, psoriasis, two enzyme therapies for Pompe disease, and an antibiotic for the treatment of intra-abdominal infections that are multi-resistant to first-line treatments.

Therapeutic extensions of medicines already reimbursed by the NHS fall within the scope of the treatment of idiopathic pulmonary fibrosis, lung and thyroid cancer, and primary immune thrombocytopenia (ITP).